Specifically, serelaxin normalised the contribution of vasoconstrictor prostanoids to endothelial dysfunction and suppressed diabetes-induced hyper-responsiveness to Ang II in the mesenteric artery. The gene discussed is AGT; the disease is endothelial dysfunction.